Alimera Sciences, Inc. (ALIM) recently announced that it has entered into a definitive agreement with Minnesota-based biopharmaceutical company, ANI Pharmaceuticals, Inc. (ANIP) , wherein the latter has agreed to acquire Alimera.Shares of Alimera shot up 75.9% on Jun 24 following the news announcement, while ANIP shares rose 7.3%.Per the deal terms, Alimera is set to be acquired by ANIP for $5.50 per share in cash and its investors will be entitled to a contingent value right for up to $0.50 per share if ce ...

MILWAUKEE, June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals.Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.In the transaction, Alimera public shareholders will receive only $5.50 per share in cash at closing and one non-tradable contingent valu ...

Alimera Sciences (NASDAQ:ALIM) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ:ANIP).This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock. It also includes contingent rights of 50 cents per share. These are payable if certain revenue goals are met in 2026 and 2027.Investors in Alimera Sciences will note that this offer is a 75% premium to ALIM stock’s prior closing price. It’s also an 82% premiu ...

Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. Are you looking for signals & alerts from pro-traders? Sign-up to Invezz Signals™ for FREE. Takes 2 mins.ANI shares are roughly flat at writing.  Alimera Sciences stock valued at a 75% premiumCopy link to sectionANI Pharmaceuticals is willing to pay $5.50 in cash for each share of Alimera Sciences. It has als ...

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to ...

ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the "Compensation Comm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34703 Alimera Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0028718 (Stat ...

Alimera Sciences, Inc. (NASDAQ:ALIM) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President U.S. Operations Philip Ashman - President, International Operations Conference Call Participants Chase Knickerbocker - Craig-Hallum Yi Chen - H.C. Wainwright & Company Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator L ...

Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -200%. A quarter ago, it was expected that this eye drug developer would post earnings of $0.02 per share when it actually produced a loss of $0.07, delivering a surprise of -450%.Over the last four quarters, the company ...

Exhibit 99.1 FOR IMMEDIATE RELEASE Alimera Sciences Reports First Quarter 2024 Results · Net Revenue up 70% to $23 Million vs. Q1 2023 · Global End User Demand Up 23% vs. Q1 2023 · Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced fi ...